Monitor Q4 2026 DefenCath sales for volume stability and any early Medicare Advantage contract announcements. The Heron deal closing in Q1 2027 and the REZZAYO PDUFA date in Q1 2027 are the next major catalysts. Watch for the TPN study strategy decision before the next quarterly call.
Drugs in focus
CRMD drug pipeline →rezafungin
▲ Bullish Named in this DEFA14A- Impact
- Phase
- Approved
- Time to market
- Already marketed (approved March 2023). The supplemental indication for prophylaxis has a PDUFA target in Q1 2027, with a promotional launch targeted for H2 2027 if approved.
- Next catalyst
- NDA filing · 2026
What to watchWatch for the specific PDUFA date announcement (Q1 2027) for the REZZAYO prophylaxis sNDA, which is the next major binary catalyst. The stock trades at ~$7.85 with ~$15.33 analyst target (95% upside) but carries ~20% short interest, suggesting a potential squeeze setup if the sNDA is approved. Monitor Q3 earnings on Nov 11, 2026 for REZZAYO revenue trajectory in the currently approved indications.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CorMedix reported Q3 2026 consolidated revenue of $54.5 million (down 48% YoY from $104.3M due to the DefenCath post-TDAPA transition) and a GAAP net loss of $14.7 million vs. net income of $108.6M in Q3 2025. The company reaffirmed FY2026 revenue guidance of $325M-$345M and narrowed adjusted EBITDA guidance to $130M-$140M. Management deferred 2027 DefenCath revenue guidance due to CMS's new quarterly add-on methodology, while noting the Heron asset acquisition (expected to close Q1 2027) should be immediately accretive.
Key Facts
- Q3 2026 consolidated revenue $54.5M vs $104.3M in Q3 2025 (-48% YoY)
- DefenCath net sales $17.2M (incl $5M favorable estimate change); Q3 2025 had $104.3M total revenue with 1 month of Melinta
- GAAP net loss $14.7M ($0.19/share) vs net income $108.6M ($1.42/share) in Q3 2025
- Adjusted EBITDA $3.1M vs $71.9M in Q3 2025
- Cash and equivalents $355.2M at quarter end
- FY2026 revenue guidance reaffirmed $325M-$345M; adjusted EBITDA guidance narrowed to $130M-$140M
- DefenCath 2027 revenue guidance deferred; CMS quarterly add-on mechanism will result in average reimbursement below $8.32
- Heron asset acquisition expected to close Q1 2027; $45M-$60M annualized cost synergies targeted by end of 2027
- REZZAYO sNDA for prophylaxis accepted with priority review; FDA target action in Q1 2027
- Phase 3 TPN study enrollment 'meaningfully behind' timelines; alternative regulatory pathways being evaluated
Financial Impact
Q3 revenue declined ~48% YoY to $54.5M; GAAP net loss of $14.7M vs prior-year net income of $108.6M; adjusted EBITDA fell to $3.1M from $71.9M
Risk Factors
- DefenCath 2027 revenue uncertainty due to CMS quarterly add-on methodology; management deferred guidance
- Phase 3 TPN study enrollment delays may require alternative regulatory pathway, potentially delaying label expansion
- Heron acquisition subject to stockholder approval, regulatory clearance, and closing conditions
- Heron portfolio revenue range ($125M-$150M for 2027) faces external risks from CINVANTI litigation and potential Azurity launch
- ORBACTIV/KIMYRSA contracted after generic Dalvance launch; base business growth limited
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (CRMD), Batch item 1 | 0001213900-26-120018 |
| Document: ea0312211-8k_cormedix.htm | 0001213900-26-120016 |
| Document: 0001213900-26-120018-index-headers.html | 0001213900-26-120018 |
| Document: 0001213900-26-120018-index.html | 0001213900-26-120018 |
| Document: 0001213900-26-120018.txt | 0001213900-26-120018 |
| 8-K Filing (CRMD), Batch item 6 | 0001213900-26-120016 |
| Document: ea0312211-8k_cormedix.htm | 0001213900-26-120018 |
| Document: 0001213900-26-120016-index-headers.html | 0001213900-26-120018 |
| Document: 0001213900-26-120016-index.html | 0001213900-26-120018 |
| Document: 0001213900-26-120016.txt | 0001213900-26-120018 |
Track record
22 reports on CRMD
9 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 10 of 12 went positive at some point.
Filters
- Nov 13, 20263d ago DEFA14A / 8-K Bearish 6/10 Viewing Entry $4.71 Now $4.70 +0.32% settles Nov 23
- Nov 12, 20265d ago Press Release Bearish 5/10 Entry $4.84 Now $4.70 +3.00% settles Nov 19
- Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.70 −11.42% settles Nov 18
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.70 −11.42% settles Nov 18
- Nov 9, 20268d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.70 −14.17% ▼ −11.88% −10.19% vs SPY
- Nov 9, 20268d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.70 −14.17% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202615d ago 8-K Neutral 5/10 No price data
- Nov 2, 202615d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.70 −12.89% ▲ +1.48% +1.41% vs SPY
- Oct 19, 202629d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.70 −36.38% ▲ +7.59% +7.73% vs SPY
- Oct 19, 202629d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.70 −36.38% ▲ +8.74% +8.88% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers